摘要
由严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus-2,SARS-CoV-2)引起的疾病被命名为新型冠状病毒肺炎(coronavirus disease 2019,COVID-19),是一种具有强传染性、高易感性、长潜伏期的传染病。病毒刺突蛋白受体结合结构域(receptor binding domain,RBD)和细胞血管紧张素转换酶2(angiotensin-converting enzyme 2,ACE2)之间的相互作用使得SARS-CoV-2顺利进入细胞。本文对SARS-CoV-2与ACE2的相关作用机制进行了简单概述,对目前针对SARS-CoV-2中和单克隆抗体、纳米抗体的最新研究进展进行了总结,探讨了新冠肺炎的发展过程和抗体药物的研究方向,以期为包括新冠肺炎在内的新发、突发传染病中和抗体药物的研发提供参考。
Coronavirus disease(COVID-19)is an infectious disease caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2),with strong contagiousness,high susceptibility and long incubation period.cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain of the viral spike protein and the cellular angiotensin-converting enzyme 2(ACE2).Here,we briefly reviewed the mechanisms underlying the interaction between SARS-CoV-2 and ACE2,and summarized the latest research progress on SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies,so as to better understand the development process and drug research direction of COVID-19.This review may facilitate understanding the development of neutralizing antibody drugs for emerging infectious diseases,especially for COVID-19.
作者
陈玉磊
林锦锦
郑培义
曹敏杰
金腾川
CHEN Yulei;LIN Jinjin;ZHENG Peiyi;CAO Minjie;JIN Tengchuan(College of Ocean Food and Biological Engineering,Jimei University,Xiamen 361021,Fujian,China;School of Basic Medical Sciences,University of Science and Technology of China,Hefei 230027,Anhui,China)
出处
《生物工程学报》
CAS
CSCD
北大核心
2022年第9期3173-3193,共21页
Chinese Journal of Biotechnology
基金
中国科学院战略先导项目(XDB29030104)
福建省自然科学基金(2021J01838)
国家自然科学基金(31870731,31772049)
国家重点研发计划(2018YFD0901004)。
